fidrisertib (IPN60130) / Ipsen 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
1 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
fidrisertib (IPN60130) / Ipsen
FALKON, NCT05039515 / 2020-002858-24: A Study to Assess the Effectiveness and Safety of 2 Dosage Regimens of Oral Fidrisertib (IPN60130) for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP).

Active, not recruiting
2
113
Europe, Canada, Japan, US, RoW
IPN60130, Fidrisertib, Placebo
Clementia Pharmaceuticals Inc., Ipsen
Fibrodysplasia Ossificans Progressiva
07/25
03/29

Download Options